알츠하이머 치매의 행동심리증상에서 비정형 항정신병약물

키워드

참고문헌 (50)

1. Jost BC, "The evolution of psychiatric symptoms in Alzheimer’s disease : a natural history study", J Am Geriatr Soc, 44, pp.1078~1081 (1996)
2. Steinberg M, "Point and 5-year period prevalence of neuropsychiatric symptoms in dementia : the Cache County Study", Int J Geriatr Psychiatry, 23, pp.170~177 (2008)
3. Benoit M, "Behavioral and psychologic symptoms in Alzheimer’s disease: results of the REAL.FR study", Rev Med Interne, 24(Suppl 3), pp.319s~324s (2003)
4. Chan DC, "Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis", J Gerontol A Biol Sci Med Sci, 58, pp.548~554 (2003)
5. Aalten P, "Behavioral problems in dementia : a factor analysis of the neuropsychiatric inventory", Dement Geriatr Cogn Disord, 15, pp.99~105 (2003)
6. Haupt M, "A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease", Dement Geriatr Cogn Disord, 11, pp.147~152 (2000)
7. Ballard C, "A prospective study of psychotic symptoms in dementia sufferers : psychosis in dementia", Int Psychogeriatr, 9, pp.57~64 (1997)
8. Hart DJ, "A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer’s disease", Int J Geriatr Psychiatry, 18, pp.1037~1042 (2003)
9. Ballard C, "Neuroleptic drugs in dementia : benefits and harm", Nat Rev Neurosci, 7, pp.492~500 (2006)
10. Glick ID, "Treatment with atypical antipsychotics : new indications and new populations", J Psychiatr Res, 35, pp.187~191 (2001)
11. Liperoti R, "The use of atypical antipsychotics in nursing homes", J Clin Psychiatry, 64, pp.1106~1112 (2003)
12. Briesacher BA, "The quality of antipsychotic drug prescribing in nursing homes", Arch Intern Med, 165, pp.1280~1285 (2005)
13. Katz IR, "Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group", J Clin Psychiatry, 60, pp.107~115 (1999)
14. Brodaty H, "A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia", J Clin Psychiatry, 64, pp.134~143 (2003)
15. Schneider LS, "Psychosis of Alzheimer disease : validity of the construct and response to risperidone", Am J Geriatr Psychiatry, 11, pp.414~425 (2003)
16. Mintzer J, "Risperidone in the treatment of psychosis of Alzheimer disease : results from a prospective clinical trial", Am J Geriatr Psychiatry, 14, pp.280~291 (2006)
17. Schneider LS, "Risk of death with atypical antipsychotic drug treatment for dementia : meta-analysis of randomized placebo-controlled trials", JAMA, 294, pp.1934~1943 (2005)
18. Sernyak MJ, "Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia", Am J Psychiatry, 159, pp.561~566 (2002)
19. Zheng L, "Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients : the CATIE-AD study", Am J Psychiatry, 166, pp.583~590 (2009)
20. "Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances"[URL]
21. Street JS, "Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities:a double-blind, randomized, placebo-controlled trial", The HGEU Study Group. Arch Gen Psychiatry, 57, pp.968~976 (2000)
22. De Deyn PP, "Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease", Int J Geriatr Psychiatry, 19, pp.115~126 (2004)
23. De Deyn P, "Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study", J Clin Psychopharmacol, 25, pp.463~467 (2005)
24. Mintzer JE, "Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses", Am J Geriatr Psychiatry, 15, pp.918~931 (2007)
25. Streim JE, "A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease", Am J Geriatr Psychiatry, 16, pp.537~550 (2008)
26. Ballard C, "Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease : randomised double blind placebo controlled trial", BMJ, 330, pp.874~ (2005)
27. Tariot PN, "Quetiapine treatment of psychosis associated with dementia:a double-blind, randomized, placebo-controlled clinical trial", Am J Geriatr Psychiatry, 14, pp.767~776 (2006)
28. Paleacu D, "Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer’s disease patients: a 6-week, double-blind, placebo-controlled study", Int J Geriatr Psychiatry, 23, pp.393~400 (2008)
29. Schneider LS, "Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials", Am J Geriatr Psychiatry, 14, pp.191~210 (2006)
30. Schneider LS, "Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease", N Engl J Med, 355, pp.1525~1538 (2006)
31. Ballard C, "The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease", Cochrane Database Syst Rev, (1), pp.CD003476~ (2006)
32. Tan L, "Efficacy and safety of atypical antipsychotic drug treatment for dementia : a systematic review and meta-analysis", Alzheimers Res Ther, 7, pp.20~ (2015)
33. Maher AR, "Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults : a systematic review and meta-analysis", JAMA, 306, pp.1359~1369 (2011)
34. Katz I, "The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia : a meta-analysis of 4placebo-controlled clinical trials", Int J Geriatr Psychiatry, 22, pp.475~484 (2007)
35. Liperoti R, "Antipsychotics for the treatment of behavioral and psychological symptoms of dementia(BPSD)", Curr Neuropharmacol, 6, pp.117~124 (2008)
36. Gauthier S, "Management of behavioral problems in Alzheimer’s disease", Int Psychogeriatr, 22, pp.346~372 (2010)
37. Zhong KX, "Quetiapine to treat agitation in dementia: a randomized, doubleblind, placebo-controlled study", Curr Alzheimer Res, 4, pp.81~93 (2007)
38. Kurlan R, "Quetiapine for agitation or psychosis in patients with dementia and parkinsonism", Neurology, 68, pp.1356~1363 (2007)
39. De Deyn PP, "A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia", Neurology, 53, pp.946~955 (1999)
40. Katz IR, "Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial", Am J Geriatr Psychiatry, 12, pp.499~508 (2004)
41. Kallin K, "Why the elderly fall in residential care facilities, and suggested remedies", J Fam Pract, 53, pp.41~52 (2004)
42. Vigen CL, "Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease : outcomes from CATIE-AD", Am J Psychiatry, 168, pp.831~839 (2011)
43. Kennedy J, "Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer’s dementia", Int J Geriatr Psychiatry, 20, pp.1020~1027 (2005)
44. Herrmann N, "Do atypical antipsychotics cause stroke?", CNS Drugs, 19, pp.91~103 (2005)
45. Wooltorton E, "Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials", CMAJ, 170, pp.1395~ (2004)
46. Kryzhanovskaya LA, "A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia", J Clin Psychiatry, 67, pp.933~945 (2006)
47. Gill SS, "Atypical antipsychotic drugs and risk of ischaemic stroke : population based retrospective cohort study", BMJ, 330, pp.445~ (2005)
48. Mehta S, "Risk of cerebrovascular adverse events in older adults using antipsychotic agents : a propensity-matched retrospective cohort study", J Clin Psychiatry, 71, pp.689~698 (2010)
49. Gerhard T, "Comparative mortality risks of antipsychotic medications in community-dwelling older adults", Br J Psychiatry, 205, pp.44~51 (2014)
50. Maust DT, "Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm", JAMA Psychiatry, 72, pp.438~445 (2015)

관련 논문AI추천